On 4 August 2026, International Flavors & Fragrances filed a Form 8-K that did something more informative than announce a quarter. It reclassified the business it is selling to CVC Capital Partners as discontinued operations, and in doing so published, for the first time, a clean split between the part of IFF that serves food formulators and the part that does not.
The numbers in that split are the story. The business being sold — texturants, emulsifiers, plant-based solutions and other specialty ingredients — ran at an EBITDA margin of roughly 13.9% in 2025. The segment IFF is keeping that contains its cultures, enzymes and food biosciences business ran at 25.0% in the second quarter of 2026.
That is the decision. IFF is selling the layer that texturises plant protein and keeping the layer that ferments things.
What the deal actually is
On 29 May 2026, IFF announced an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners. The headline number is approximately $4.3 billion of enterprise value, at an enterprise-value-to-EBITDA multiple of approximately 10x. IFF retains an approximately 10% minority equity interest, which it puts at approximately $200 million.
The 10x arithmetic checks out against the disclosed earnings: IFF stated that in 2025 the Food Ingredients business being divested generated nearly $3.1 billion in annual sales and approximately $430 million of EBITDA. At $4.3bn, that is 10.0x.
What the May release did not state, and the August results release did, is the cash figure. IFF is selling the disposal group for net cash proceeds of approximately $3.8 billion, subject to customary transaction adjustments.
| Figure | Value | Source |
|---|---|---|
| Enterprise value | ~$4.3 billion | 29 May 2026 announcement |
| EV/EBITDA multiple | ~10x | 29 May 2026 announcement |
| 2025 sales of the divested business | ~$3.1 billion | 29 May 2026 announcement |
| 2025 EBITDA of the divested business | ~$430 million | 29 May 2026 announcement |
| Retained minority stake | ~10%, ~$200 million | 29 May 2026 announcement |
| Net cash proceeds | ~$3.8 billion | 4 August 2026 results release |
| Expected close | End of Q2 2027 | 8-K, 4 August 2026 |
Practical consequence: the gap between the $4.3bn headline and the $3.8bn of net cash is about $500 million. IFF does not break down what sits in that gap. Anyone modelling this transaction should use the cash figure and treat the enterprise value as the valuation statement it is, not as a receipt. This is the same headline-versus-proceeds distinction we found in two French fermentation rounds, at a different order of magnitude.
The margin gap is why
IFF’s continuing operations — Taste, Scent and Health & Biosciences — delivered a second-quarter 2026 adjusted operating EBITDA margin of 20.9%. Including discontinued operations, the same quarter was 19.7%. IFF states both figures and calls the difference an improvement.
Below that consolidated line, the segment detail makes the ranking explicit.
| Segment (Q2 2026) | Sales | Adjusted operating EBITDA | Margin |
|---|---|---|---|
| Taste | $688m | $124m | 18.0% |
| Health & Biosciences | $601m | $150m | 25.0% |
| Scent | $665m | $134m | 20.2% |
| Continuing operations, total | $1.95bn | $408m | 20.9% |
| Discontinued operations | $827m | $140m | 16.9% (computed) |
| Including discontinued operations | $2.78bn | $548m | 19.7% |
All figures except the computed 16.9% are stated by IFF in the 4 August results release. The 16.9% is $140m divided by $827m and is our arithmetic, not IFF’s.
Health & Biosciences is the segment that carries food enzymes, cultures and probiotics; IFF attributes its Q2 growth to “Grain Processing, Food Biosciences & Animal Nutrition”. It is the highest-margin segment IFF has, by five points over Scent and seven over Taste, and it is not for sale.
A basis caveat, because it matters. The 13.9% we derive for the divested business comes from the May announcement’s $430m of “EBITDA” on ~$3.1bn of 2025 sales. The 25.0% for Health & Biosciences is IFF’s adjusted operating EBITDA margin for a single quarter of 2026. These are not the same measure over the same period, and the difference between EBITDA and adjusted operating EBITDA at a company that reports specified items in the hundreds of millions is not trivial. The direction of the gap is unambiguous and large. The precise width of it is not something IFF has published on a single consistent basis, and we are not going to pretend otherwise.
The full-year framing IFF gave in August is the closest thing to a like-for-like: continuing operations guided to $7.4–7.6 billion of sales and $1.53–1.60 billion of adjusted operating EBITDA, excluding approximately $3.2 billion of sales and approximately $520 million of adjusted operating EBITDA related to discontinued operations. That implies roughly 20.6–21.1% for what stays and about 16.3% for what goes — but the discontinued figure covers the Food Ingredients disposal group plus the separately divested Soy Crush, Concentrates and Lecithin businesses up to their 2 March 2026 disposal, so it is not a clean read on the CVC perimeter either.
Where the $3.8 billion goes
This is the part with a direct bearing on anyone building in this industry, and IFF has been unusually specific about it.
The company announced a sequenced capital allocation framework with a stated leverage objective of 2.0x to 2.5x net debt to EBITDA. Against that:
- Over $1 billion of net proceeds applied to reducing outstanding debt.
- An enhanced $2.5 billion share repurchase authorisation, which includes approximately $400 million remaining from a prior authorisation.
- Of that, a $500 million accelerated share repurchase to be executed in the second half of 2026 — before the transaction closes.
- The remaining $2.0 billion after close, with the whole programme targeted for completion by the end of 2027.
Net debt to credit adjusted EBITDA stood at 2.5x at the end of Q2 2026, on a combined continuing-and-discontinued basis.
Add it up: over $1bn to debt, $2.5bn to buybacks. That is $3.5bn of a $3.8bn cash figure allocated to the balance sheet and to shareholders. No portion of the announced framework is earmarked for capacity, plant, or reinvestment in food ingredients. IFF frames the strategic logic as concentrating resources on Taste, Scent and Health & Biosciences — but the disclosed use of proceeds is deleveraging and repurchase, not capital expenditure in any segment.
Practical consequence: if you are a formulator whose texturant and emulsifier systems come from IFF Food Ingredients, the capital released by this sale is not going into the assets that make your inputs. It is going to IFF’s lenders and IFF’s shareholders. Whatever investment the business receives from 2027 will be CVC’s decision, funded on CVC’s terms.
The stranded-cost number nobody quotes
IFF disclosed that approximately $100 million of corporate and functional expenses previously allocated to the Food Ingredients business are expected to remain with IFF after close. It expects to eliminate roughly two thirds within the first year following close and substantially all within two years.
That is a real figure against the transaction. Against approximately $430m of 2025 EBITDA leaving the building, $100m of cost staying behind for a year or more is a material haircut to the economics of the separation — and it is the kind of number that appears in a results release and never in a headline.
It also puts a floor under the timeline. Close is expected by the end of the second quarter of 2027. Full stranded-cost remediation runs to roughly mid-2029. This is a three-year transaction, not an event.
Why this belongs on an alternative-protein desk
It would be easy to file a $4.3bn flavours-and-fragrances divestiture as general food-industry M&A. Two things make it specific to this beat.
First, the portfolio description names plant-based solutions explicitly. Both the 8-K and the CVC release describe the disposal group as “texturants, emulsifiers, plant-based solutions, and other specialty ingredients”. Texturants and emulsifiers are not adjacent to alternative protein formulation — they are the functional backbone of it. Our own work on what actually changes when you formulate with fermentation-derived protein is about exactly this layer: the systems that make a novel protein behave in a finished product.
Second, the split is diagnostic. A company with full visibility into both businesses has concluded that the fermentation-and-enzymes layer is worth keeping at 25% margins and the texturising layer is worth 10x EBITDA to a financial buyer. That is a market-clearing price for the industrial middle of food, set by an informed seller. It sits oddly against the valuations attached to pre-revenue alternative protein platforms, and it is a more useful benchmark than most of what the sector quotes at itself. We reached a similar conclusion from the opposite direction when we looked at who is actually acquiring alternative protein assets and at Agronomics carrying its portfolio at cost while its own shares traded at a discount.
The counter-argument
The strongest case against reading this as a retreat from food ingredients is that it is not one — it is a portfolio reshuffle at a company that has been unwinding the DuPont Nutrition & Biosciences merger for three years. IFF divested Pharma Solutions and Nitrocellulose in May 2025, the Soy Crush, Concentrates and Lecithin businesses on 2 March 2026, and now Food Ingredients. On that reading, the sale says nothing about the attractiveness of texturants; it says IFF is a flavours and biosciences company that acquired a commodity ingredients estate and is finishing the job of shedding it.
That reading is fair and probably correct as to intent. It does not change the operational facts a buyer of these ingredients faces: a new owner, a 2027 close, a $100m stranded-cost programme, and a capital allocation framework that returns the proceeds rather than reinvesting them.
There is also a genuine case that CVC ownership is good for the business. IFF’s stated rationale for retaining 10% is participation in “future value creation under its new ownership”, and CVC’s own statement points to the business’s “global reach and proprietary technical capabilities”. A dedicated owner with no competing claim on capital from a fragrance division is not obviously worse for a texturants business than being the low-margin segment inside a company optimising for margin.
What we could not establish
- The composition of the ~$500 million difference between the ~$4.3 billion enterprise value and the ~$3.8 billion of net cash proceeds. IFF describes the proceeds as “subject to customary transaction adjustments” but does not itemise taxes, fees, debt-like items or working-capital adjustments.
- A like-for-like margin for the CVC perimeter. The 2025 figure is EBITDA; the 2026 figures are adjusted operating EBITDA; the FY2026 discontinued figures include the SCL businesses. We have flagged each basis rather than blending them.
- Any disclosed capital expenditure plan for the Food Ingredients business under CVC. Neither the CVC release nor IFF’s results release states one.
- Whether specific alternative-protein texturant lines are inside or outside the disposal perimeter. The perimeter is described by category, not by product line, and “other minor perimeter adjustments” is IFF’s own language.
- The 2025 sales and EBITDA of the SCL disposal group separately. Without it, the FY2026 ~$3.2bn / ~$520m discontinued figures cannot be cleanly attributed to the CVC perimeter.
What to watch
Three testable things, in order of how soon they resolve:
- The $500 million accelerated share repurchase. IFF says it will execute this in the second half of 2026 — before the sale closes. If it slips, the sequencing framework is under strain.
- Regulatory clearance. The 8-K conditions the close on “applicable information and/or consultation requirements and customary closing conditions, including regulatory approvals, where required”. A texturants and emulsifiers portfolio of this scale changing hands is a plausible candidate for competition review in more than one jurisdiction. Watch for filings before mid-2027.
- Whether the first-year stranded-cost target is met. IFF has committed to eliminating roughly two thirds of ~$100 million within twelve months of close. That is a specific, checkable claim with a date attached, and it will appear in the results releases.
If the close holds to the end of Q2 2027 and the buyback completes by the end of 2027, IFF will have converted a 13.9%-margin ingredients estate into debt reduction and share count reduction inside eighteen months. That is a coherent piece of corporate finance. It is also, for anyone who buys texturants, a change of counterparty that has already been decided and will take another year to arrive.